Genetic Institute Inc v Kirin-Amgen Inc (No 2)

The plaintiffs, Genetic Institute Inc, brought an action against the defendants, Kirin-Amgen Inc, in the Federal Court of Australia. The dispute centres on the validity and enforceability of certain patent rights held by the plaintiffs in relation to recombinant DNA technology, specifically in the production of erythropoietin, a hormone used to treat anaemia. The case involves allegations of patent infringement and seeks damages for unauthorised use of the patented technology.

The primary legal issues before the court included the scope and interpretation of the patent claims, the validity of those claims, and whether the defendants had indeed infringed the plaintiffs' patent rights. The court was required to determine the technical meaning of specific terms used in the patents and assess whether the defendants' activities fell within the scope of the claims. Additionally, the court needed to consider the enforceability of the patents in light of any potential invalidating prior art or public use.

The court meticulously examined the patent specifications and the technical documentation provided. It found that the claims were clear and unambiguous, and the defendants' activities did indeed constitute an infringement. The court held that the patents were valid and enforceable, rejecting the defendants' arguments that the claims were invalid due to lack of novelty or inventive step. The court further noted that the prior art cited by the defendants did not anticipate the claimed invention. The judgment concluded that the plaintiffs' patents were valid and enforceable and that the defendants had infringed them. The court reserved costs and set a date for a subsequent directions hearing to manage the next steps of the litigation process.